TRD & Anxiety · Hayward, CA

Treatment-resistant depression can make a person feel painfully alone. After trying medication after medication, it’s easy to start thinking maybe I am the problem. Maybe my brain is too broken. Maybe remission is not possible for me. When anxiety is also part of the picture, those thoughts get louder. And the research, awkwardly, agrees with part of the experience — anxious depression really is harder to treat. But harder to treat is not the same as untreatable, and the distinction matters for everything that happens next.

In the STAR*D trial, the largest real-world depression treatment study ever conducted in the United States, Fava and colleagues found that roughly 53% of participants had anxious depression — major depression with clinically meaningful anxiety symptoms — and that this group reached remission less often and more slowly than patients without significant anxiety, with higher side-effect burden and more serious adverse events along the way.^[1] That’s not an unusual finding. It’s the modal pattern. If you have depression and anxiety together, you’re not a niche case. You’re the median patient in a major trial.

What TRD with anxiety actually feels like

TRD is exhausting on its own. Anxiety adds a second layer of suffering — and a particular kind of cognitive trap. Depression tells you that nothing will change. Anxiety tells you that something terrible will happen if you try. Together they can make life feel like a room with no door: too tired to move, too afraid to rest, too ashamed to ask for help, too discouraged to believe help will work.

The combination changes everyday relationships. Partners and friends become harder to be around — not because anything is wrong with them, but because you feel like a burden, or because you need more reassurance than anyone can sustainably provide. Goals start to feel dangerous, because wanting something means you could fail at it. Daily life shrinks into survival: get through today, avoid the next trigger, hide how bad it is, and try not to disappoint anyone.

The world starts to look hostile through this lens. A delayed text feels like rejection. A small mistake feels like proof of failure. A future plan feels unrealistic before you’ve even started it. This is the cruelest part of depression and anxiety together: the illness doesn’t only change how you feel. It changes what your brain presents as true.

Feelings are real. Conclusions from those feelings are not always facts.

This is where good treatment becomes both biological and educational. The fear is real. The hopelessness is real. The exhaustion is real. The conclusions your brain produces from those feelings during anxious TRD are not automatically accurate.

Nothing will work is a thought. I am too damaged is a thought. Remission is impossible for me is a thought. They feel like facts because depression and anxiety give them enormous emotional force. Part of recovery is learning to challenge them while simultaneously treating the biology underneath. Nobody recovers from TRD through willpower or positive thinking. But it is possible to stop treating every hopeless thought as a reliable prediction about the future.

That educational piece matters more than it sounds. The more clearly a patient understands how depression and anxiety distort attention, memory, threat perception, and self-worth, the easier it becomes to fight the illness at the level of belief instead of being fought by it.

How TRD-related anxiety can look different from “ordinary” anxiety

Anxiety in TRD often doesn’t present as discrete panic episodes or specific phobias. It presents as a kind of background certainty that any effort will end badly. Less I’m nervous about this meeting, more any effort I make will prove I’m a failure.

It can show up as fear of disappointing people, fear of being rejected, fear of trying and crashing again, fear that hope itself is dangerous because being disappointed again is unbearable. Some people become extremely sensitive to signs of rejection — a neutral tone, a missed call, or a short text feels like evidence that someone is pulling away. Others become afraid of goals because goals create the possibility of failure. Even basic responsibilities can feel emotionally loaded, because every unfinished task seems to confirm the depression’s narrative: you cannot handle life.

This is anxiety filtered through depression, shame, exhaustion, and the specific weariness of repeated treatment disappointment. It deserves its own clinical attention, not just dismissal as “the depression talking.”

Why treatment has to address both at the same time

When anxiety travels with TRD, the treatment plan usually has to be more precise than for either condition alone. On the depression side, options include the standard TRD interventions: medication switches, augmentation strategies, esketamine (SPRAVATO), transcranial magnetic stimulation (TMS), and structured psychotherapy. The evidence base for each in this comorbid context is substantial.

The 2022 GEMINI trial published in Biological Psychiatry tested deep TMS specifically for anxious depression — major depressive disorder with clinically significant anxiety symptoms — and found significantly greater symptom improvement with active stimulation than sham across the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and the Clinical Global Impressions scale, supporting the 2021 FDA clearance of Deep TMS for anxious depression as a specific indication.^[2]

For esketamine, post-hoc analyses of the pivotal trials examined whether comorbid anxiety changed outcomes. The Jha 2023 analysis in Journal of Affective Disorders found that intranasal esketamine produced clinically meaningful TRD response regardless of baseline irritability — a relevant marker of anxious-depressive comorbidity — suggesting esketamine retains efficacy even in the harder-to-treat anxious phenotype.^[3] The FDA prescribing information for SPRAVATO confirms the monotherapy indication for adults with treatment-resistant depression (approved January 21, 2025) as well as the original combination indication with an oral antidepressant.^[4]

On the anxiety side, the work is usually psychological. Cognitive-behavioral therapy adapted for anxious depression helps identify and unhook the thought-and-avoidance patterns that keep both conditions reinforcing each other. Behavioral activation rebuilds life through small actions before motivation returns — a critical reordering of cause and effect for patients who’ve been waiting for motivation to come back first. When trauma is part of the picture, trauma-focused therapy (EMDR, prolonged exposure, cognitive processing therapy) addresses the underlying threat learning that anxious depression often sits on top of.

What the data says about combining these interventions

The original STAR*D effectiveness study, Rush and colleagues 2006, established the now-foundational observation that about a third of patients with major depression do not reach remission even after multiple medication trials.^[5] For the anxious-depression subset specifically, the remission rate drop is substantial. This is the empirical reason TRD with comorbid anxiety requires intensified, often layered treatment — not because the patient is failing, but because the underlying clinical picture is genuinely harder.

The McClintock and colleagues consensus recommendations for clinical application of rTMS in depression, published in Journal of Clinical Psychiatry in 2018, explicitly include patients with anxious depression in the eligible population — not as a contraindication or exclusion.^[6] The Blumberger THREE-D trial in 2018, the largest non-inferiority trial in the field, established intermittent theta-burst stimulation (iTBS) as effectively equivalent to standard 10 Hz rTMS for TRD, broadening the practical options for treatment-resistant patients who also need shorter session times.^[7]

Naturalistic real-world data also supports TMS efficacy in difficult-to-treat populations. The Carpenter 2012 multisite naturalistic study of TMS in clinical practice found meaningful symptom reduction in patients similar to those treated in everyday outpatient psychiatry — not just the carefully selected RCT population.^[8]

The shape of disciplined hope

The goal of explaining all of this is not to insist that recovery is easy or that the next medication will be the one. The goal is what might be called disciplined hope: a clear-eyed understanding of the illness that allows you to stop believing every terrifying conclusion it produces, while continuing to pursue evidence-based treatment with realistic expectations about what each step can and cannot do.

Disciplined hope looks like: knowing that anxious depression has lower remission rates than nonanxious depression, AND knowing that 47% of STAR*D patients with anxious depression did still reach remission across the trial steps. It looks like: knowing that TMS and esketamine retain efficacy in anxious-depressive comorbidity, AND knowing that no single treatment works for everyone. It looks like: respecting the felt reality of “nothing will work” without surrendering to it as a prediction.

If you are reading this in the middle of an anxious-depressive episode that has resisted multiple treatments, the most useful thing to know is probably this: the pattern you are in is well-described in the literature, the treatment options for this exact pattern have expanded substantially in the last decade, and the people who do best in this clinical situation tend to be the ones who keep working the problem with a clinician who actually understands TRD with anxiety as a specific entity — not as a personality defect.

The bottom line

TRD with anxiety can feel like your brain has become a prosecutor, building the case against your recovery one anxious thought at a time. The case feels overwhelming. It is not the same thing as a medical fact.

Anxious depression is one of the most-studied comorbidities in clinical psychiatry, with its own evidence base for TMS (Deep TMS specifically FDA-cleared for anxious depression in 2021), for esketamine (efficacious across the anxious-depressive phenotype), and for combined pharmacotherapy plus structured psychotherapy. The treatments that work for non-anxious TRD generally still work in this population — they may need to be sequenced, dosed, or combined differently, but the underlying biology and clinical evidence still apply.

You are not alone in this pattern. You are not failing because anxiety is tangled into your depression. Remission remains worth fighting for, even when the illness insists it isn’t.

By Nefretiri Abat, JD, PMHNP-BC — Founder, Exxceed Wellness, Hayward CA. This article is for general education and does not substitute for individualized medical advice. If you are in immediate danger or considering self-harm, please call 988 (Suicide & Crisis Lifeline) or your local emergency number.